{"id":"ad35-rsv-fa2","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"target":"RSV fusion protein","explanation":"Ad35.RSV.FA2 uses a replication-incompetent adenovirus serotype 35 vector to deliver RSV fusion protein antigens. The vaccine aims to stimulate both humoral and cellular immune responses against RSV, potentially providing protection against RSV infection and disease.","oneSentence":"Adenovirus serotype 35-vectored vaccine designed to elicit immune responses against RSV fusion protein."},"_scrapedAt":"2026-03-28T04:32:54.422Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123437,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"RSVpreF","brand":"Abrysvo","company":"Pfizer","rationale":"Approved RSV vaccine for older adults and maternal immunization"},{"name":"RSVPreF3","brand":"Arexvy","company":"GSK","rationale":"Approved RSV vaccine for older adults"},{"name":"nirsevimab","brand":"Beyfortus","company":"Sanofi/AstraZeneca","rationale":"Monoclonal antibody for RSV prevention in infants"}],"description":"Ad35.RSV.FA2 is an investigational vaccine developed by Crucell Holland BV targeting respiratory syncytial virus (RSV) infection. The vaccine is based on adenovirus serotype 35 vector technology and is in early-stage clinical development for prevention of RSV disease.","indications":{"approved":[{"status":"investigational","condition":"Respiratory syncytial virus infection","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT02440035","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-04-21","conditions":"Healthy Participants","enrollment":48},{"nctId":"NCT02561871","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09","conditions":"Respiratory Syncytial Viruses, Respiratory Tract Infections","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-61187191-AAA"],"phase":"phase_1","status":"active","brandName":"Ad35.RSV.FA2","genericName":"Ad35.RSV.FA2","companyName":"Crucell Holland BV","companyId":"crucell-holland-bv","firstApprovalDate":"","aiSummary":"Ad35.RSV.FA2 is a vaccine being studied for its safety, tolerability, and immunogenicity in healthy adult participants. The study, NCT02440035, is evaluating the vaccine in combination with Ad26.RSV.FA2 for its potential to prevent Respiratory Syncytial Viruses and Respiratory Tract Infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}